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Differential expression of microRNAs during melanoma
progression: miR-200c, miR-205 and miR-211 are downregulated
in melanoma and act as tumour suppressors
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1MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, MRC Human Genetics Unit, Western General Hospital, Crewe Road,
Edinburgh, EH4 2XU, UK; 2Department of Pathology, NHS Lothian, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK;
3Edinburgh Cancer Centre, NHS Lothian, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; 4Department of Dermatology,
NHS Lothian, Level 1, Lauriston Building, Lauriston Place, Edinburgh, EH3 9HA, UK
BACKGROUND: The incidence of malignant melanoma is increasing faster than that for any other cancer. Histological examination of skin
excision biopsies remains the standard method for melanoma diagnosis and prognosis. Significant morphological overlap between
benign and malignant lesions complicates diagnosis, and tumour thickness is not always an accurate predictor of prognosis.
METHODS: To identify improved molecular markers to support histological examination, we used microarray analysis of formalin-fixed
and paraffin-embedded samples from different stages of melanomagenesis to identify differentially expressed microRNAs (miRNAs).
Differential expression was validated by qRT–PCR, and functional studies were carried out after transfection of miRNA precursors or
inhibitors into melanoma cells to modulate miRNA expression.
RESULTS: In all, 20 miRNAs showed highly significant differential expression between benign naevi and either primary or metastatic
melanomas, the majority being downregulated in melanoma, whereas only 2 miRNAs, namely miR-203 and miR-205, were
differentially expressed between primary and metastatic melanomas. In functional in vitro assays, overexpression of miR-200c and
miR-205 inhibited anchorage-independent colony formation and overexpression of miR-211 inhibited both anchorage-independent
colony formation and invasion.
CONCLUSION: We have identified a series of differentially expressed miRNAs that could be useful as diagnostic or prognostic markers
for melanoma and have shown that three miRNAs (namely miR-200c, miR-205 and miR-211) act as tumour suppressors.
British Journal of Cancer (2012) 106, 553–561. doi:10.1038/bjc.2011.568 www.bjcancer.com
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Globally, the incidence of malignant melanoma is increasing faster
than that for any other cancer. In the United Kingdom, melanoma
has become the second most common cancer among young
adults (Cancer Research UK Cancer Statistics, 2011; http://
info.cancerresearchuk.org/cancerstats/). Although some melano-
mas may show an unpredictable course, the histological measure
of tumour thickness (Breslow thickness) remains the best
predictor of outcome (Balch et al, 2001). However, it is not always
an accurate indicator of biological behaviour. Although 5-year
survival for patients with tumours o1 mm thick is 490%, a
significant minority with thin melanomas go on to develop
metastatic disease, whereas not all thick lesions metastasise. The
mainstay of treatment is surgical, which may be curative for thin
melanomas, emphasising the importance of early clinical detection
and correct histological diagnosis. Histological examination of
skin excision biopsies remains the diagnostic gold standard
(Carlson et al, 2005); a challenging task because of the wide
morphological spectrum of cutaneous melanocytic tumours and
the lack of firm diagnostic criteria.
There is an urgent need for molecular markers to corroborate
the diagnosis from histological examination. To be clinically
useful, markers must be readily applicable to formalin-fixed and
paraffin-embedded (FFPE) tissues and differences between benign
and malignant lesions must be marked. There has been significant
recent progress in understanding the genetic defects in melanoma,
but few markers have proven to be of clinical significance and no
single molecular marker has been informative over a wide range of
lesion types (Carlson et al, 2005; Blokx et al, 2010).
MicroRNAs (miRNAs) are a large family of short non-coding
RNAs that function as gene regulators. They can act as both
oncogenes and tumour suppressors (Ventura and Jacks, 2009) and
have advantages as melanoma biomarkers. Like mRNAs, they can
be screened by array-based methods, but because of their very small
size, they are not susceptible to degradation in FFPE samples. This is
particularly important for melanoma in which the entire primary
tumour is usually required for histology; hence, supply of fresh
material for reliable mRNA microarray is severely limited.
Initial screening identified miRNAs in melanoma cell lines the
expression of which was significantly different compared with
other cancer cell lines (Blower et al, 2007; Gaur et al, 2007).
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MicroRNAs involved in melanomagenesis have now been identified
from expression studies on fresh tissue and functional studies in cell
lines (Mueller and Bosserhoff, 2009; Caramuta et al, 2010). Our
approach has been to screen FFPE samples from different stages of
melanomagenesis to identify differentially expressed miRNAs for
functional studies, which have shown that three of these miRNAs act
as tumour suppressors in malignant melanoma cells.
MATERIALS AND METHODS
Tissue samples
Formalin-fixed and paraffin-embedded samples were obtained
from the Royal Infirmary of Edinburgh: benign naevi, recurrent
and non-recurrent primary melanomas and metastatic melanomas.
Details of the samples on the array are given in Supplementary
Table 1. The local ethics committee granted approval for this study
(REC reference number: 06/S1103/9). Samples of benign naevi and
metastatic melanomas for RNA isolation were obtained from
2-mm diameter cores of FFPE blocks. For primary melanomas,
tumour tissue was separated from adjacent non-tumour tissue by
microdissection of 10-mM sections. Suitable areas for coring and
dissection were marked by the pathologist. RNA was isolated from
FFPE samples (3–4 cores, or scrapings from 15 sections per
isolation) using the RecoverAll Total Nucleic Acid Isolation Kit
(Ambion, Life Technologies Ltd, Paisley, UK) following the
manufacturer’s protocol. Total RNA yields from FFPE samples
were 0.4–9.0 mg and A260/280 ratios ranged from 1.58 to 2.07.
miRNA microarray
Illumina miRNA microarray (Illumina, San Diego, CA, USA;
catalogue no. MI 501-1001, part no. 11297743) was carried out on
200 ng RNA extracted from FFPE and cultured cell samples.
Analysis of the built-in controls using the Illumina BeadStudio
application showed that array data were of good quality and
established gene expression detection limits. To preserve as many
differentially expressed miRNAs as possible, miRNA signals were
not background subtracted. Instead, a filter (detection P-value
o0.01 in at least 80% of samples) was applied. From a total of 1146
probes, 862 (75.2%) passed through the filter. Thereafter, log2-
transformed data were normalised using the Quantile method and
analysed using R version 2.8.1 software (www.r-project.org/).
Hierarchical clustering was performed using Cluster 3.0 (http://
bonsai.ims.u-tokyo.ac.jp/~mdehoon/software/cluster) software and
the TreeView programme (http://jtreeview.sourceforge.net/) was
used for interactive graphical analysis. City block distance
(Manhattan distance) and complete linkage clustering methods
were used to analyse log2-transformed data. Differentially
expressed miRNAs on the array were identified using the
Limma Bioconductor package for R (http://www.bioconductor.org/
biocLite.R). miR-92 was chosen as internal control for the
qRT–PCR assays because of its abundant and relatively constant
expression in cell and FFPE samples. The average miR-92
expression signal for the different samples on the microarray is
shown in Supplementary Figure 1.
Mammalian cell culture
The origin of immortalised human melanocyte lines, Hermes 1 and
Hermes 4a, has been described previously (Gray-Schopfer et al,
2006). Human malignant melanoma cell lines (A375, C32, G361
and WM115) were obtained from the European Collection of Cell
Cultures (Salisbury, UK). HBL was obtained from Gentaur
(GENTAUR Europe, Kampenhout, Belgium). EDMEL3 was isolated
by Ewan Brown from a melanoma metastasis. A375 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf serum, 25 U ml1 penicillin and
25mg ml1 streptomycin. RNA was isolated using RNA-Bee (AMS
Biotechnology (Europe) Ltd, Abingdon, UK).
Transfection
RNA was mixed with the siPORT NeoFX Transfection Agent
(Ambion), and reverse transfection of A375 cells was carried out
following the manufacturer’s protocol. Cell number per well:
1 105 for 12-well and 2 105 for 6-well plates. Transfection
efficiencies for precursor- and anti-miRNAs were first optimised
using FAM-labelled pre-miR and anti-miR negative controls
(Ambion), the uptake of which into cells was monitored by flow
cytometry. Final concentration of RNA and transfection agent:
RNA, 30 nM for precursors, 150 nM for inhibitors; siPORT NeoFX,
8 ml per well in 12-well plates, 16 ml per well in 6-well plates. These
conditions consistently yielded transfection efficiencies 485%
with A375 cells.
Gene expression assays
Both miRNA and mRNA expressions were determined by TaqMan
assays. Assays for individual miRNAs and mRNAs, reverse
transcription and PCR kits were all obtained from Applied
Biosystems (Carlsbad, CA, USA). The miRNA expression was
standardised against the miR-92 control and mRNAs were
standardised against b-actin. A standard curve was run for each
gene-specific PCR reaction to determine whether the PCR
efficiencies of target and control gene were equivalent. In every
case, the slope of the plot of log dilution factor vs DCT was o0.1;
hence, the comparative CT method could be used to determine
relative miRNA and mRNA concentrations (Livak and Schmittgen,
2001).
Proliferation and cell-cycle distribution assays
Growth rate was determined using the sulforhodamine B colori-
metric growth assay (Vichai and Kirtikara, 2006). Cell-cycle
distribution was determined by flow cytometry of propidium
iodide-stained nuclei.
Methylcellulose colony-formation assay
Cells (1 104) were added in 2 ml of 1.4% methylcellulose in
complete DMEM onto a 2 ml layer of 1.8% agarose in complete
DMEM in 6-well tissue culture plates. After incubation, colony size
was determined by image analysis of microscopic images.
Invasion assay
The transwell migration assay was carried out as described
previously (Serrels et al, 2010). After incubation, cells were dye-
labelled and visualised in the Matrigel basement membrane matrix
(BD Biosciences, Oxford, UK; Cat. no. 354 234) at 10-mM intervals
by confocal sectioning. The relative cell number in each section,
determined from fluorescence intensity, was analysed using ImageJ
software (NIH, http://rsb.info.nih.gov/ij/) and expressed relative to
the cell number in the section that represented the base of the
transwell filter. Significance tests for the results of this and the
other cell-based assays were carried out using one-way ANOVA or
Student’s t-test.
RESULTS
Hierarchical clustering of miRNA expression patterns
from FFPE and cultured cell samples
MicroRNA microarray expression data were obtained from 52
FFPE specimens (11 benign naevi, 10 recurrent and 10
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non-recurrent primary melanomas, 21 metastatic melanomas) and
15 cell lines. The cell lines were 2 immortalised human melanocytes
and 13 human malignant melanoma lines (A375, C32, G361,
WM115, HBL and the EDMEL3 series). EDMEL3 was isolated from
a late-recurring distal melanoma metastasis. Early and later
passages, as well as subclones with different morphologies
(epithelial, spindle cell, mixed) were available. Cells retrieved back
into culture from EDMEL3 xenografts were also included. Further
details of the samples on the array are given in Supplementary
Table 1. Unsupervised cluster analysis was carried out on the entire
data set. The clustering obtained along with part of the heatmap is
shown in Supplementary Figure 2 to illustrate the EDMEL3 cluster,
which has high expression for the 20 miRNAs selected compared
with most of the other samples. The similarity between the
metastasis, from which the EDMEL3 cell line was derived, and
the EDMEL3 cell line series is illustrated in Supplementary Figure 2.
However, all the melanoma cell lines clustered separately from the
FFPE samples, stressing the importance of not relying entirely on
cell culture data for studies on melanomagenesis. For FFPE
samples, there was no clear clustering distinction between naevi,
primaries and metastases, perhaps reflecting the molecular hetero-
geneity of melanoma. The pattern of clustering of FFPE samples
was not affected when the melanoma and melanocyte cell data were
excluded from the analysis. However, significant differences
between the groups in the expression of individual miRNAs were
found as described below.
Melanoma-specific miRNA expression profile
The 735 target miRNAs on the array included 470 well-annotated
human miRNAs and 265 additional miRNAs. The expression
of each was compared individually between the naevus, primary
and metastatic melanoma groups to identify melanoma-specific
miRNAs. In all, 113 miRNAs were differentially expressed in the
comparison between primary melanomas and benign naevi
(adjusted P-value o0.05). In all, 97 miRNAs were differentially
expressed between metastatic melanomas and benign naevi.
In the comparison between metastatic and primary melanomas,
only 25 miRNAs were differentially expressed. The full lists of
the differentially expressed miRNAs are shown in Supplementary
Table 2.
There were too many differentially expressed miRNAs for all to
be investigated further. To narrow the candidate list, more
stringent criteria were added (log2 fold expression change 42
and adjusted P-value o0.001). Overall, 20 miRNAs remained in
the primary melanoma vs naevus comparison, 19 in the metastatic
melanoma vs naevus comparison and only 2 in the metastatic vs
primary comparison (Table 1). There was considerable overlap
between the three lists (Figure 1).
Only two miRNAs, miR-205 and miR-203, were present in all
three comparisons and both were downregulated in melanomas.
Their expression was decreased from the naevus through the
primary melanoma to the metastatic melanoma group. All five
members of the miR-200 family, miR-200a, miR-200b, miR-200c
and miR-141 and miR-429 were decreased in the metastatic
melanoma vs benign naevus comparison and three members (miR-
200a, miR-200b and miR-141) were also downregulated in primary
melanomas compared with benign naevi. Expression of miR-20b
and miR-675 was increased in primary and metastatic melanomas
in comparison with benign naevi. miR-211 was downregulated in
metastatic melanomas relative to benign naevi (adjusted P-value
0.0087, log2 fold expression change 2.4), but did not pass through
the stringent filter. It was also chosen for qRT–PCR verification
because of the large expression difference found between melano-
cyte and melanoma cell lines (see later).
Table 1 Top differentially expressed microRNAs in benign naevi,
primary and metastatic melanoma FFPE tissues
Primary vs naevus Metastatic vs naevus Metastatic vs primary
MiR Adj. P Exprn miR Adj. P Exprn miR Adj. P Exprn
603 1.45E-12 6.9 205 3.88E-16 37.5 205 4.42E-09 6.9
663b 7.04E-10 10.8 203 2.06E-15 64.0 203 4.42E-09 10.4
1826 8.69E-10 4.7 183 6.41E-11 11.5
200b* 1.26E-09 11.5 200b* 1.27E-10 13.7
183 2.47E-09 8.4 200c 1.27E-10 8.8
149 5.13E-07 5.3 603 1.26E-09 4.6
200a 1.55E-06 6.9 200b 8.86E-08 12.7
205 2.49E-06 5.4 200a 8.86E-08 8.6
675 4.87E-06 8.3 663b 9.07E-08 7.0
99a 6.97E-06 4.1 141 2.24E-06 7.6
200b 6.97E-06 8.2 149 4.38E-06 4.4
455-5p 8.39E-06 5.5 429 1.91E-05 5.8
182 1.76E-05 7.1 21 2.42E-05 4.3
203 2.91E-05 6.1 224 3.06E-05 8.9
494 4.99E-05 7.5 182 3.06E-05 6.5
455-3p 1.93E-04 4.4 142-5p 1.02E-04 4.8
20b 2.55E-04 5.4 20b 2.26E-04 5.4
141 5.14E-04 4.5 675 2.90E-04 5.3
198 7.98E-04 5.5 9 5.51E-04 7.4
224 9.86E-04 5.8
Abbreviations: Adj. P¼ adjusted P-value; Exprn¼ expression difference; FFPE¼
formalin fixed and paraffin embedded. Differentially expressed miRNAs with an
Exprn 4±4-fold and an Adj. P o0.001 are shown, ranked by adjusted P-value.
In X vs Y comparison, when Y4X, the expression fold change is negative.
Primary vs Benign Metastatic vs Benign
Metastatic vs Primary
3 Up
miR-21
miR-142-5p
miR-9
2 Down
miR-205
miR-203
3 Up
miR-1826
miR-494
miR-198
3 Down
miR-99a
miR-455-5p
miR-455-3p
4 Up
miR-603
miR-663b
8 Down
miR-200b*
miR-183
miR-149
miR-200a
2 Down
miR-200c
miR-429
miR-200b
miR-182
miR-141
miR-224
miR-675
miR-20b
0
00
Figure 1 Top differentially expressed microRNAs between benign naevi,
primary and metastatic melanoma. Venn diagram showing the relationship
between the differentially expressed miRNAs from the comparisons shown
in Table 1. For each X vs Y comparison, up means expression was higher in
X, down means expression was lower in X. Naevus group, n¼ 11; primary
group, n¼ 20; metastasis group, n¼ 21.
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Verification of differential miRNA expression during
melanomagenesis
An additional eight benign naevi were included in the verification
experiments. For every miRNA examined, the qRT–PCR data
verified the microarray result. The four members of the miR-200
family (miR-200a, miR-200b, miR-200c and miR-141) showed
significant decreased expression between benign and malignant
tissues from 15- to 200-fold (Figure 2A). However, only miR-141
also showed a significant decrease between primary and metastatic
melanomas. The expression of miR-211 was decreased in both
primary (4-fold) and metastatic melanomas (6-fold) compared
with benign naevi (Po0.001), but again there was no significant
difference between primaries and metastases. For miR-203 and
miR-205, there was a 410-fold decrease from benign naevi to
primary melanomas and a 4100-fold decrease from primary to
metastatic melanomas. All expression differences between groups
were highly significant (Figure 2B). The expression was 10-fold
higher in melanomas compared to benign naevi for miR-20b and
20-fold higher for miR-675, although in each case, there was no
significant difference between primary and metastatic melanomas
(Figure 2C).
Although all nine miRNAs showed the same trend when
comparing the non-recurrent and recurrent primary groups as
observed in the primary with metastasis comparison, none of the
differences were significant (Supplementary Figure 3).
Overexpression of miR-200c in melanoma cells causes
increased expression of E-cadherin mRNA
Both miR-200c and miR-205 were selected for functional studies
because both act as tumour suppressors in other cancers by
reversing epithelial-mesenchymal transition (EMT), in which one
of the key events is reduction in E-cadherin levels. E-cadherin
expression is controlled by the ZEB1 and ZEB2 transcriptional
repressors, which are targets of both miR-200c and miR-205
(Maragkakis et al, 2009).
The expression of miR-200c and miR-205 was significantly
reduced in melanomas compared to benign naevi. The expression
of both miRNAs was also low in the human malignant melanoma
cell line, A375 (data not shown). For functional studies, precursors
of miR-200c and miR-205 were transfected into A375 cells and
expression was assayed by qRT–PCR. Levels of both miR-200c
(Figure 3A) and miR-205 (Supplementary Figure 4A) were
dramatically increased in precursor-transfected cells compared
with non-transfected negative control and transfected scramble
control groups. Levels were highest at 24h (4104-fold increase for
miR-200c) and then dropped over the time course.
The expression of ZEB2 was downregulated in the pre-200c
group on all 3 days (Figure 3B). The reduction was significant on
days 1 (4.5-fold) and 2 (2-fold) compared with the scrambled
control, indicating that the inhibitory effect of miR-200c reduced
over the time course as its level decayed. The expression of ZEB2
was also reduced in the pre-205 group on day 1, but the reduction
was not significant (Supplementary Figure 4B). The expression of
ZEB2 was also decreased on days 1 and 2 in cells transfected with
both precursors, the decrease being significant on day 2
(Figure 3C).
There was no indication of an additive effect of miR-200c and
miR-205 on the reduction of ZEB2 mRNA levels; hence, expression
levels of the transcriptional target of ZEB2, E-cadherin, were only
assayed in A375 cells with elevated miR-200c levels. E-cadherin
mRNA levels were increased on all 3 days and the elevation was
significant on days 1 and 2 (3- and 4-fold, respectively; Figure 3D),
compatible with the reduction in ZEB2 mRNA observed on the
same days.
Overexpression of miR-200c and miR-205 in melanoma
cells causes reduced anchorage-independent colony
formation
A375 cells with elevated miR-200c and miR-205 levels growing in
control medium had the same proliferation rate and cell-cycle
distribution for 4 days after transfection as controls (data not shown).
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Figure 2 microRNA expression changes during melanoma progression. (A) Downregulated miRNAs miR-200a, miR-200b, miR-200c, miR-141 and
miR-211. (B) Downregulated miRNAs miR-203 and miR-205. It must be noted that the Y axis is on a log10 scale. (C) Upregulated miRNAs miR-20b
and miR-675. Mean expression (±s.e.m.) of each miRNA, determined by qRT–PCR, is shown relative to miR-92 and normalised to the Naevus group
mean. Naevus group, n¼ 12–17; primary, n¼ 20; metastasis, n¼ 14. *Po0.05; **Po0.01; ***Po0.001.
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We next investigated the effect of elevated levels of miR-200c
and miR-205 on tumourigenicity and invasion assays. Anchorage-
independent colony formation in methylcellulose is a powerful
in vitro surrogate assay for tumourigenicity in xenograft assays.
A375 cells were set up in methylcellulose immediately after
transfection with miR-200c and miR-205 precursors and with a
control scrambled miRNA. Colony size on day 6 was significantly
smaller for the miR-200c and miR-205 precursor-transfected
groups, but again there was no indication of an additive effect
with both precursors (Figure 4).
To determine whether elevated levels of miR-200c and miR-205
influence the invasive ability of A375 melanoma cells, a transwell
migration assay through Matrigel was set up immediately after
transfection and analysed on day 5 (Supplementary Figure 5). For
the miR-200c and miR-205 precursor-transfected groups, the
relative cell numbers 40 mM into the Matrigel appeared lower than
in the scramble and negative controls, but the differences were not
significant.
Overexpression of miR-211 in melanoma cells causes both
reduced anchorage-independent colony formation and
invasiveness
The expression of miR-211 was 410-folder lower in all four
melanoma cell lines examined than in the two immortalised
melanocyte lines, and in A375, the expression was 104-fold lower
(Figure 5A). When the miR-211 precursor was transfected into
A375 cells, the expression was dramatically increased on all 3 days
after transfection, increasing levels to those seen in immortalised
melanocytes (Figure 5B).
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Figure 3 Ectopic expression of miR-200c in melanoma cells causes
ZEB2 downregulation and E-cadherin upregulation. Expression was
determined by qRT–PCR after transfection of A375 melanoma cells with
miR-200c precursor, or a combination of miR-200c and miR-205
precursors (dark shading), or a scrambled control miRNA (intermediate
shading); non-transfected negative control (light shading). Mean relative
expression levels (±s.e.m.) from three independent experiments are
shown (A) Expression of miR-200c relative to miR-92 and normalised to
the mean of the negative control. (B) Expression of ZEB2 mRNA after
transfection with miR-200c precursor relative to b-actin and normalised to
the mean of the negative control. (C) Expression of ZEB2 mRNA after
transfection with miR-200c and miR-205 precursors relative to b-actin.
(D) Expression of E-cadherin mRNA after transfection with miR-200c
precursor relative to b-actin. *Po0.05; ***Po0.001.
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Figure 4 Ectopic expression of miR-200c in melanoma cells causes
reduced anchorage-independent colony formation. A375 cells were
transfected with miR-200c precursor, or a combination of miR-200c and
miR-205 precursors, or a scrambled control miRNA and colony formation
in methylcellulose was determined after 6 days. Non-transfected A375 cells
were used as a negative control. (A) Histogram showing the mean size
(±s.e.m.) of 30 colonies from each group, normalised to the mean of the
negative control group. *Po0.05; ***Po0.001. (B) Representative colony
images on day 6.
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As with miR-200c and miR-205 overexpression, there were no
obvious changes in proliferation rate or cell-cycle distribution in
A375 cells with elevated miR-211 levels growing in control
medium; hence, we proceeded to anchorage-independent colony-
formation and invasion assays. Colony size in methylcellulose,
determined on day 6, was significantly smaller for miR-211
precursor-transfected groups than for both scrambled and non-
transfected controls (Figure 5C and D). Migration through
Matrigel in the transwell migration assay was also significantly
reduced on day 5 for miR-211 precursor-transfected cells (Figure
5E and F).
Reduction of miR-20b has no effect on melanoma cells
The expression of miR-20b was significantly increased in melano-
mas compared with benign naevi. A miR-20b inhibitor miRNA was
transfected into A375 cells so that the effects of decreased miR-20b
levels could be studied. Expression was significantly decreased at
24 and 48h (5- and 2-fold respectively; Supplementary Table 3).
The reduction for miR-20b was much less than the increases
observed for miR-200c, miR-205 and miR-211 and the effect
diminished more rapidly after transfection. Perhaps unsurpris-
ingly, no effect of miR-20b reduction in A375 cells was observed in
cell proliferation, cell-cycle distribution, anchorage-independent
colony-formation and invasion assays (data not shown).
DISCUSSION
As an initial step to identifying improved diagnostic and
prognostic molecular markers for melanoma, we carried out a
comprehensive microarray study incorporating fixed tissues
samples representing the key stages in melanomagenesis and a
range of melanocyte and melanoma cell lines. As such, we believe it
to be the largest and most complete study of miRNA expression in
melanoma so far.
Melanoma cell lines did not cluster together with FFPE
melanoma tissues, questioning the validity of many of the
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Figure 5 Ectopic expression of miR-211 in melanoma cells causes reduced anchorage-independent colony formation and invasion. A375 cells were
transfected with miR-211 precursor, or a scrambled control miRNA and colony formation in methylcellulose and invasion in a transwell migration assay was
determined. (A) Expression of miR-211 in melanoma and melanocyte cell lines. Immortalised melanocyte lines Hermes 1 (HER1) and Hermes 4a (HER4);
melanoma lines EDMEL3, G361, C32 and A375. Mean miR-211 expression from two independent experiments relative to miR-92 and normalised to HER1
is shown. (B) Overexpression of miR-211 in A375 melanoma cells after transfection of precursor miR-211. Mean relative expression levels (±s.e.m.) of
miR-211 relative to miR-92 and normalised to the mean of the negative control from three independent experiments are shown. (C) Reduced
methylcellulose colony formation in A375 cells after transfection of miR-211 precursor. Histogram shows the mean size (±s.e.m.) of 30 colonies from each
group on day 6, normalised to the mean of the negative control group. (D) Representative colony images on day 6. (E) Reduced invasion in A375 cells after
transfection of miR-211 precursor. Cells migrating through Matrigel in a transwell inverse invasion assay were quantified after 5 days at the 40 mM layer. The
relative cell number was determined as the ratio of cell number in the 40 mM layer/cell number in the origin (0 mM layer). Results represent average ratios
(±s.e.m.) of six microscope fields for each group, normalised to the negative control group. (F) Representative stacked confocal images from the origin
(0mM layer) to the tenth layer (90 mM). *Po0.05; ***Po0.001.
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melanoma miRNA expression studies so far, which have been
carried out exclusively on cell lines. The naevus, primary and
metastatic FFPE samples were not found in discrete separate
clusters, but were instead intermingled. A similar intermingling of
melanocyte, primary and metastatic melanoma cell lines has been
reported previously (Mueller et al, 2009), and we conclude that
cluster analysis of miRNA expression does not distinguish the
different stages of melanomagenesis.
Analysis of differential expression during melanomagenesis of
individual miRNAs was more informative. In all, 20 miRNAs
passed through a very strict filter for differential expression
between benign naevi and primary or metastatic melanoma, and
only 2, miR-203 and miR-205, passed through the same filter for
differential expression between primary and metastatic melanoma.
Nine of these miRNAs were selected for qRT– PCR validation and
all passed the test. The majority of the differentially expressed
miRNAs identified were downregulated during melanomagenesis.
All members of the miR-200 family examined showed a 10-fold
reduction from benign naevi to primary melanoma, but in only
one, miR-141, was there a further significant reduction from
primaries to metastases. The largest differential downregulation
was shown by miR-203 and miR-205, in which expression was
10-fold lower in primaries than in naevi, and was then reduced
a further 100-fold from primaries to metastases. Both miR-20b
and miR-675 were two of the minority of miRNAs that were
upregulated during progression from benign naevi to primary
melanoma, but again with no increase on metastasis.
Firm diagnostic criteria for melanoma based on histological
features alone are difficult to establish owing to the wide
morphological range of melanocytic naevi and significant mor-
phological overlap between benign lesions and malignant mela-
noma. There can be frequent disagreement on diagnosis, even
between expert dermatopathologists (Grant-Kels et al, 1999; Lodha
et al, 2008), and this could result in possible overtreatment and in
delayed treatment. If detection by in situ hybridisation could be
established for one or more of the most highly differentially
expressed miRNAs between benign and malignant melanocytic
lesions that we have identified, this could prove a very valuable
diagnostic tool. Indeed, this has now been reported for miR-21 and
miR-155, which were overexpressed in melanoma and in border-
line melanocytic lesions (Grignol et al, 2011). Both of these
miRNAs appear in our full list of miRNAs overexpressed in
metastatic melanoma.
During the course of this study, a number of other melanoma-
specific miRNA expression patterns have been reported, mostly
from microarray studies on cultured cells and by tissue analysis,
rather than from full microarray on FFPE tissues as in our
study (Blower et al, 2007; Gaur et al, 2007; Mueller et al, 2009).
Many of the miRNAs identified also appear in our lists. A study
comparing 8 benign naevi and 8 metastatic melanomas, but
no primary melanomas, described 31 differentially expressed
miRNAs (Chen et al, 2010). Another study included three benign
naevi, five primary and seven metastatic melanoma samples
(Philippidou et al, 2010). Comparing these two reports, which used
fewer FFPE samples, with our array results, some common differ-
entially expressed miRNAs emerge: miR-200 family, miR-20b,
miR-125b, miR-183, miR-193b, miR-203, miR-204, miR-205,
miR-211, let-7c.
Although all nine miRNAs that we validated by qRT–PCR
showed the same trend when comparing non-recurrent and
recurrent primary melanomas as observed in the primary with
metastasis comparison, none of the differences were significant.
Larger sample numbers and actual length of survival comparisons,
rather than simple recurrence status, would be required to
investigate the prognostic value of these miRNAs. Two studies
have reported prognostic miRNA expression profiles (Caramuta
et al, 2010; Segura et al, 2010); of 18 such miRNAs in Segura et al
(2010), 7 appear in our lists.
The reduced expression we observed for all five members of the
miRNA-200 family in melanomas compared with benign naevi is
consistent with previous reports (Chen et al, 2010; Philippidou
et al, 2010). However, other studies have found one of more
miRNA-200 family members upregulated in melanoma (Schultz
et al, 2008; Mueller et al, 2009). miR-205 showed the largest
reduction in expression during melanomagenesis, again consistent
with a recent report (Dar et al, 2011). The miR-200 family and
miR-205 reverse the EMT process required for metastasis by
directly targeting the 30 untranslated regions of the mRNAs for
ZEB1 and ZEB2, which are transcriptional repressors of the
E-cadherin gene in epithelial cancers (Hurteau et al, 2007; Bracken
et al, 2008; Burk et al, 2008; Korpal et al, 2008; Park et al, 2008;
Gregory et al, 2008a, b). Epithelial-mesenchymal transition also
appears to be important in a non-classical epithelium-derived
cancer like melanoma (Park et al, 2008). Study of melanoma
tissues suggested that EMT-related genes contributed to the
promotion of the metastatic phenotype (Alonso et al, 2007).
Suppression of melanoma cell growth in vitro and in xenografts
and induction of senescence by overexpression of miR-205 has
recently been reported (Dar et al, 2011). There is also now one
report that miR-200a and miR-200c, although not suppressing
melanoma cell invasion, had different effects on the mode of
invasion (Elson-Schwab et al, 2010).
We chose miR-200c and miR-205 for our functional study in
A375 melanoma cells and found that transient upregulation caused
reduced anchorage-independent colony formation in an in vitro
surrogate assay for tumourigenicity. There was no additive effect
when both miRNAs were elevated together and no effect on
invasiveness was observed in transwell migration assays. For
miR-200c, this was accompanied by a reduction in levels of the
ZEB2 target and an increase in its target, E-cadherin. Thus, our
data demonstrate that miR-200c acts as a tumour suppressor in
melanoma, the same role that has been attributed to the miR-200
family in other cancers, and confirm the role of miR-205 as a
tumour suppressor in melanoma. Demonstration of stronger
tumour suppressor and target pathway effects would require
stable, rather than transient increased expression.
miR-211 showed significantly reduced expression in melanomas
compared with naevi, but was mainly chosen for functional studies
because of the 1000-fold decreased expression we observed in most
of the melanoma cells lines examined compared with immortalised
melanocytes. Reduced expression of miR-211 in melanoma
compared with melanocyte cell lines (Caramuta et al, 2010; Boyle
et al, 2011), in an invasive melanoma cell line compared with a less
invasive derivative (Mueller et al, 2009), in primary melanomas
compared with benign naevi (Chen et al, 2010; Jukic et al, 2010)
and in melanomas that have spread to sentinel lymph nodes
compared with those that have not (Glud et al, 2010) has been
reported previously. Transient ectopic expression of
miR-211 in melanoma cells significantly decreased both ancho-
rage-independent colony formation and invasiveness. Reports
published since our study began have also demonstrated the
tumour-suppressor ability of miR-211 in invasion assays only in
melanoma cell lines and have identified a number of targets,
including transforming growth factor receptor II and the BRN2
transcription factor, which represses expression of MITF, the
master transcription factor regulator for melanocytes (Levy et al,
2010; Mazar et al, 2010; Boyle et al, 2011).
miR-20b was chosen for functional studies because it was one of
the minority of miRNAs that showed highly significant increased
expression in melanomas compared with naevi. It modulates
c-MYC and acts as an oncogene in human T-cell leukaemia and
mouse mammary cancers (Landais et al, 2007; Sun et al, 2009).
Transfection with an anti-miR was used to transiently knockdown
miR-20b levels in melanoma cells, but no changes in anchorage-
independent colony formation or invasiveness were found, possibly
because of the small reduction achieved, particularly when compared
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with the large increases obtained for miR-200c, miR-205 and miR-211.
An alternative explanation could be that miR-20b functions in
carcinogenic processes, such as tumour angiogenesis, that we did
not assay for (Hua et al, 2006; Lei et al, 2009).
In conclusion, we have carried out a comprehensive microarray
analysis on naevi and melanoma samples to identify and validate
miRNAs that are differentially expressed during melanomagenesis.
Such miRNAs could serve as markers to improve melanoma
diagnosis and prognosis. Functional assays on selected differen-
tially expressed miRNAs in cultured melanoma cells have
identified miR-200c and miR-205 as tumour suppressors in
anchorage-independent colony-formation assays and miR-211 as
a tumour suppressor in both anchorage-independent colony-
formation and invasion assays.
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